This presentation contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this presentation. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may
cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Annual Report on Form 10-Kand other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
This presentation concerns product candidates that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. These product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.
This presentation also contains estimates and other statistical data made by independent parties and by ALX Oncology relating to market size and growth and other industry data. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of ALX Oncology's future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.
1
CD47: OVEREXPRESSED IN CANCER AND MARKER OF WORSE PROGNOSIS
CD47-Expression levels in cancer and normal tissue
Survival by CD47 expression-AML
The Cancer Genome Atlas (TCGA)
Majeti et al, Cell 2009
2
CD47/SIRPα IS A MYELOID CHECKPOINT - "DO NOT EAT ME SIGNAL"
Tumor cell
CD47
"Don't eat me signal"
SIRPα
SHP 1/2
SHP 1/2
Myosine depolarization
Macrophage
Inhibition of
Cytoskeleton
phagocytosis
rearrangement
Journal of Immunology Research, vol. 2020, Article ID 9435030, 8 pages, 2020. https://doi.org/10.1155/2020/9435030
3
CD47/SIRP⍺ IS A MYELOID CHECKPOINT-THERAPEUTIC IMPLICATION
PD-L1/PD-1 Interaction
T Cell
T-Cell Receptor
PD-1
Tumor
PD-L1
Antigen
MHC Class I
Cancer Cell
CD47/SIRPα Interaction
Macrophage
SIRPα
Fc Receptor/ LRP/ etc
Anti-Cancer
Antibody
Azacitidine
Chemotherapy
CD47
Radiation
etc
Tumor
Cancer Cell
Antigen
CD47/SIRP⍺ "Don't Eat Me" signal counters the phagocytic "Eat Me" signal
similar to PD-L1/PD-1 inhibiting T-cell activation triggered by TCR antigen recognition
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
ALX Oncology Holdings Inc. published this content on 13 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 May 2021 18:28:02 UTC.
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a donât eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
ALX ONCOLOGY HOLDINGS INC. 
